RxDoctor Payments Data

Mark Hill, DO

Family Medicine · Bronx, NYNPI 1053354084

Payments from drug & device makers

$36,939in general payments, 2019–2025

Across 1,120 payments — averaging $32.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$7K
  • AstraZeneca$5K
  • Bayer$2K
  • GSK$2K
  • Viiv Healthcare Company$2K
  • Boehringer Ingelheim$2K
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$5,70015%
  • Travel & lodging$1,0583%
  • Food & beverage$29,64680%
  • Education$5351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Indivior Inc.33$7,241
AstraZeneca176$5,188
Bayer75$2,455
GSK85$2,119
Viiv Healthcare Company33$2,075
Boehringer Ingelheim54$2,063
Gilead51$1,972
AbbVie(2 entities)83$1,547
Regeneron Healthcare Solutions, Inc.35$1,269
Novo Nordisk34$988
Lilly USA, LLC45$977
Sanofi34$738
Shield Therapeutics Inc24$707
Merck30$573
Amarin Pharma, Inc.40$572
Idorsia Pharmaceuticals US Inc20$569
Astellas Pharma US Inc16$545
Amgen(2 entities)18$441
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)10$427
Pfizer26$427
Corcept Therapeutics21$381
Lundbeck LLC15$276
Kowa Pharmaceuticals America, Inc.16$253
Novartis14$248
Daiichi Sankyo Inc.6$232
Exact Sciences11$226
Johnson & Johnson13$214
Orexo US, Inc.13$199
Otsuka America Pharmaceutical, Inc.8$170
Aytu Biopharma, Inc.9$156
Neurocrine Biosciences, Inc.2$129
Sanofi-aventis U.S. LLC3$128
Verona Pharma, Inc.5$119
Biohaven Pharmaceutical Holding Company Ltd.1$111
Cumberland Pharmaceuticals, Inc.4$86
Ardelyx, Inc.3$79
Phathom Pharmaceuticals, Inc.4$72
Hikma Pharmaceuticals USA4$70
Redhill Biopharma Inc.3$58
Takeda Pharmaceuticals U.S.A., Inc.3$55
IBSA Pharma Inc.3$55
Scilex Pharmaceuticals Inc.3$54
Ironwood Pharmaceuticals, Inc2$53
Mannkind Corporation3$52
Braeburn Inc.2$50
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$50
Intra-sana Laboratories2$43
Genentech USA, Inc.2$39
Abbott2$38
Althera Pharmaceuticals LLC2$37
Avion Pharmaceuticals2$36
Biohaven Pharmaceuticals, Inc.2$32
Seqirus USA Inc1$30
Hologic Sales And Service, LLC1$27
Acarix USA Inc.1$26
Paratek Pharmaceuticals, Inc.1$23
Clarus Therapeutics Inc.1$19
Eisai Inc.1$18
Nestle Healthcare Nutrition Inc.1$18
Dexcom, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,939 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$34,636
Medicare patients
46
Services billed
1,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone119$88,520
EliquisApixaban117$77,865
JardianceEmpagliflozin70$58,587
OzempicSemaglutide37$47,638
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$37,731
JanuviaSitagliptin Phosphate49$31,097
LinzessLinaclotide46$27,529
JanumetSitagliptin Phos/Metformin Hcl26$25,796
SublocadeBuprenorphine12$24,913
MounjaroTirzepatide20$20,790
EntrestoSacubitril/Valsartan27$20,619
Soliqua 100-33Insulin Glargine/Lixisenatide15$14,271
FarxigaDapagliflozin Propanediol13$13,727
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl124$12,000
Incruse ElliptaUmeclidinium Bromide18$8,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$2,455$88,520119 claims
PfizerEliquis$427$77,865117 claims
Boehringer IngelheimJardiance, Jentadueto, Tradjenta$2,063$70,09393 claims
MerckJanuvia, Janumet$573$56,89375 claims
Novo NordiskOzempic$988$47,63837 claims
GSKTrelegy Ellipta, Incruse Ellipta$2,119$45,94864 claims
Indivior Inc.Sublocade, Suboxone$7,241$30,77524 claims
AbbVieLinzess, Synthroid$1,547$29,12070 claims
Lilly USA, LLCMounjaro$977$20,79020 claims
NovartisEntresto$248$20,61927 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$128$14,27115 claims
AstraZenecaFarxiga$5,188$13,72713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →